Nicholas Desjardins

Chief Financial Officer & Corporate Development Officer at Himalaya Therapeutics

Before joining Himalaya, Mr. Desjardins was a partner at ASGARD, a merchant bank, overseeing its advisory practice. Previously, he was a Director in Stifel’s Healthcare Investment Banking Group focusing on the biotech sector, and an Associate in Cowen’s Healthcare and TMT Investment Banking Groups. During his time at Cowen and Stifel, he worked on transactions in excess of $10 billion in value, including helping raise $1.4 billion in 17 IPOs. Prior to this, he worked in the Distressed Investing Group at KP Capital Partners focusing on restructuring and turnarounds, and spent ten years working in finance and operational capacities at companies in China and Asia Pacific, including PriceWaterhouse, Beijing RELTEC and MSL Express. Mr. Desjardins holds an MBA in Finance from the Yale School of Management, a BA in History from Yale College and a BS in Accounting, summa cum laude, from The State University of New York at Plattsburgh. He studied Mandarin Chinese at the National Taiwan Normal University and speaks and reads it fluently.